Xiaoyao San's dual efficacy in NAFLD and depression: Unraveling the mechanisms via network pharmacology and multi-omics
Phytomedicine · 2025-11 · 147 · 157221
DOI: 10.1016/j.phymed.2025.157221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2025-11. Verfasst von Yunxiao Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, Central Laboratory of The Lishui Hospital of Wen…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Drugs, Chinese Herbal, Depression. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program of Zhejiang Province.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) and depression represent two highly prevalent medical conditions often presenting concurrently. However, currently available pharmacological treatments rarely target both disorders simultaneously. Xiaoyao San (XYS), a traditional herbal formulation from Chinese medicine, has been clinically effective in addressing NAFLD and depressive symptoms, although its precise therapeutic mechanisms remain poorly understood. OBJECTIVE: This study aimed to investigate the underlying mechanisms of XYS in managing comorbid NAFLD and depression by employing network pharmacology (NP) and multi-omics methodologies. METHODS: A chronic restraint stress (CRS)-induced NAFLD rat model was constructed to simulate the disease conditions. The efficacy of XYS treatment was evaluated through behavioral assessments, histopathological liver examination, biochemical analyses, and measurements of inflammatory and oxidative stress (OS) biomarkers. Further, NP combined with metabolomic and proteomic techniques was applied to uncover pivotal targets and pathways, with subsequent validation via Western blotting (WB). RESULTS: XYS improved depression-like behaviors, reduced hepatic lipid deposition, and lowered levels of hepatic enzymes, blood lipids, and blood glucose. It also attenuated inflammatory and OS responses. Multi-omics analysis identified the PPARα/HMOX1/GPX4 axis as a key target. XYS modulated this pathway to inhibit ferroptosis and reduce hepatic iron accumulation. Specifically, XYS upregulated PPARα and GPX4 expression, downregulated HMOX1 expression, and decreased hepatic iron levels, alleviating both NAFLD and depression. CONCLUSION: XYS exerts therapeutic effects on NAFLD and depression through multi-target regulation, primarily by modulating the PPARα/HMOX1/GPX4 axis to inhibit ferroptosis. This study provides a novel mechanistic basis for the dual therapeutic efficacy of XYS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, Central Laboratory of The Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui Unive…
- Department of Traditional Chinese Medicine, Lishui People's Hospital, Lishui, Zhejiang 323000, China.
- Medical Laboratory Department, Sinopharm Dongfeng General Hospital, Shiyan, Hubei 442008, China.
- Department of Traditional Chinese Medicine, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang 325000, China.
- Department of Hepatology, Lishui People's Hospital, Lishui, Zhejiang 323000, China.
- School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325000, China. Electronic address: lizhiyong@wmu.edu.cn.
Förderung
- Key Research and Development Program of Zhejiang Province
Zitieren
APA
Liu, Y., Ding, X., Younas, A., Sun, X., Ni, X., Wang, S., Lv, J., Li, Z., & Shao, C. (2025). Xiaoyao San's dual efficacy in NAFLD and depression: Unraveling the mechanisms via network pharmacology and multi-omics. Phytomedicine, 147, 157221. https://doi.org/10.1016/j.phymed.2025.157221
Vancouver
Liu Y, Ding X, Younas A, Sun X, Ni X, Wang S, et al. Xiaoyao San's dual efficacy in NAFLD and depression: Unraveling the mechanisms via network pharmacology and multi-omics. Phytomedicine. 2025;147:157221. doi:10.1016/j.phymed.2025.157221
BibTeX
@article{Liu2025,
author = {Liu, Yunxiao and Ding, Xiaomei and Younas, Ayesha and Sun, Xiaoning and Ni, Xiaofen and Wang, Shuanghu and Lv, Jiaojian and Li, Zhiyong and Shao, Chuxiao},
title = {Xiaoyao San's dual efficacy in NAFLD and depression: Unraveling the mechanisms via network pharmacology and multi-omics},
journal = {Phytomedicine},
year = {2025},
volume = {147},
pages = {157221},
doi = {10.1016/j.phymed.2025.157221}
}
EUVIMED